Bethesda, Maryland 20892

  • Metastatic Cancer


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have advanced solid tumors affecting the lungs.

Study summary:

OBJECTIVES: - Determine the maximum tolerated dose and phase II dose of inhaled doxorubicin in patients with advanced solid tumors affecting the lungs. - Determine the toxicity of this regimen in these patients. - Determine the pharmacokinetic profile of inhaled doxorubicin in blood in these patients. - Determine the relationship between pharmacodynamic parameters and toxic effects of this regimen in these patients. OUTLINE: This is a dose-escalation study. Patients receive inhaled doxorubicin every 3 weeks for up to 3 doses. Patients with stable or responding disease may receive additional doses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 3 weeks and 3 months. PROJECTED ACCRUAL: Approximately 33 patients will be accrued for this study within 18-24 months.


DISEASE CHARACTERISTICS: - Histologically proven advanced cancer not curable by standard chemotherapy, radiotherapy, or surgery - Clinical evidence of primary lung or tracheal cancer OR - Metastatic cancer to the lung - Extrathoracic metastases eligible if following criteria are met: - Sites are stable - Pulmonary sites are primary life-threatening sites - Evidence that study treatment may benefit the patient - Measurable or evaluable disease - No germ cell tumor, leukemia, or lymphoma involving the lungs that is treatable with systemic agents - No complete atelectasis due to high-grade airway obstruction PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-1 Life expectancy: - More than 3 months Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin no greater than 1.0 mg/dL - AST and ALT less than 1.5 times upper limit of normal Renal: - Creatinine no greater than 1.6 mg/dL OR - Creatinine clearance at least 60 mL/min Cardiovascular: - LVEF at least 40% by MUGA scan or echocardiogram - No unstable angina, congestive heart failure, or symptomatic arrhythmias Pulmonary: - DLCO at least 50% predicted - FVC and FEV1 at least 50% predicted - Resting oxygen saturation at least 90% - Exercise oxygen saturation at least 85% - Oxygen consumption greater than 50% predicted - No prior radiation pneumonitis - No asthma - No radiation-induced pulmonary damage Other: - No hypersensitivity to doxorubicin - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after study - HIV negative - No congenital problems (e.g., cleft palate) or other anomalies that prevent tight fit of a mouthseal PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 weeks since prior biologic therapy and recovered - No prior trastuzumab (Herceptin) Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior chemotherapy and recovered - Prior doxorubicin allowed if LVEF at least 40% by MUGA scan or echocardiogram - No prior mitomycin, bleomycin, or nitrosoureas - No other concurrent systemic chemotherapy Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy and recovered - At least 12 months since prior radiotherapy to chest - No prior radiotherapy to more than 20% of total lung volume - Prior chest wall or primary breast radiotherapy allowed - Prior radioactive iodine allowed - No concurrent thoracic radiotherapy Surgery: - See Disease Characteristics - No prior total pneumonectomy Other: - No other concurrent experimental drug



Primary Contact:

Study Chair
David S. Schrump, MD
NCI - Surgery Branch

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.